气血双补胶囊对肺癌化疗增效减毒作用的临床观察.pdf

《气血双补胶囊对肺癌化疗增效减毒作用的临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、·中医中药·2013年4月第l0卷第12期气血双补胶囊对肺癌化疗增效减毒作用的临床观察朱为康李雁连强。张媛华徐夏婷陆俊骏11．上海市中医医院肿瘤科，上海200071；2．上海市中医医院医务处，上海200071；3．云南省红河州个旧市中医医院内科，云南个旧661000【摘要】目的为了观察气血双补胶囊治疗非小细胞肺癌化疗患者的疗效。方法将云南省红河州个旧市中医医院70例~P／I,细胞肺癌患者随机分为治疗组和对照组，每组各35例。两组均采用吉西他滨联合顺铂化疗2个周期，即第1天使用吉西他滨每次1000mg／m联合顺

2、铂75mg／m静脉滴注，每3周重复1次。3周为1个周期。治疗组于化疗前l周开始口服气血双补胶囊，每次3粒，每日3次，持续8周。结果治疗组Kamofsky评分增加优于对照组，差异有统计学意义(P<0．05)。治疗组和对照组有效率分别为42．9％和34．3％，差异无统计学意义(P>0．05)。治疗组血红蛋白减少发生率对照组明显减少，两组比较差异有统计学意义(P<0．05)。结论气血双补胶囊配合GP方案与单纯GP方案治疗肺癌的客观疗效相近，但前者生活质量，预防骨髓抑制，提高血红蛋白水平改善明显。f关键词】非小细胞肺

3、癌；气血双补胶囊；化疗；吉西他滨；顺铂【中图分类号】R979．1f文献标识码】Af文章编号】1673—7210(2013)04(c)一0098—03Clinicalobservationofcapsuleforinvigoratingqiandbloodonincreasingefficacyofchemotherapyandalleviatingtoxiceffectsinducedbychemother—apytorlungcancerZHUWeikanfLIYahLIANQianfZHANGYuanhu

4、asXUXiating~LUJunjun1．DepartmentofTumorDiseases，ShanghmHospitalofTraditionalChineseMedicine，Shanghai200071，China；2．MedicalDepartment，ShanghaiHospitalofTraditionalChineseMedicine，Shanghai200071，China；3．MedicalDe—payment，GejiuHospitalofTraditionalChineseMedic

5、ineofHonghePrefecture，YunnanProvince，Gejiu661000，China[Abstract]ObjectiveToobservetheeffectsofcapsuleforinvigoratingqiandbloodinthetreatmentofnon-smallcelllungcancerpatientsundergoingchemotherapy．MethodsNon—smallcelllungcancerpatientswererandomlydividedinto

6、treatmentgroupandcontrolgroup．Bothgroupsweretreatedbytwocyclesofgemcitabinepluscisplatinchemotherapy，whichisusinggemcitabine1000ms／m~pluseisplatin75mg／m2byintravenousonceforthefirstday，repeatedonceeverythreeweeks．Threeweekswasacycle．Intheweekbeforechemother

7、apy，treatmentgroupwasUS—ingcapsuleforinvigoratingqiandbloodbyoral，threecapsuleseachtime，threetimesaday，foreightweeks．ResultsKamofskyscoreintreatmentgroupincreasedmorethancontrolgroup，thedifferencebetweenthetwogroupswassig-nificant<0．05)．Effectiverateinthetr

8、eatmentgroupandcontrolgroupwere42．9％and34-3％respectively，butthereWasnosignificantdifference(P>0．05)．Comparedwithcontrolgroup，theincidenceofhemoglobinreducingintreatmentgroupwassignificantlydecreased<0．